Signaling Pathways Associated with Inflammatory Bowel Disease

Publisher： Bentham Science Publishers

E-ISSN： 2212-2710|4|2|105-117

ISSN： 1872-213X

Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.4, Iss.2, 2010-06, pp. : 105-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 3, Iss. 1, 2009-01 ,pp. : 1-16

Bentham Science Publishers

Access to resources Recommend Favorite

Rifaximin - Chitosan Nanoparticles for Inflammatory Bowel Disease (IBD)

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 11, Iss. 1, 2017-08 ,pp. : 41-52

Bentham Science Publishers

Access to resources Recommend Favorite

The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

By  

Recent Patents on Drug Delivery & Formulation, Vol. 8, Iss. 1, 2014-04 ,pp. : 3-11

Bentham Science Publishers

Access to resources Recommend Favorite

Signaling Pathways Involved in Physiopathology of Pancreatic &bgr; -Cells

By  

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 1, Iss. 3, 2007-11 ,pp. : 180-192

Bentham Science Publishers

Access to resources Recommend Favorite

Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP

By  

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 3, Iss. 1, 2009-01 ,pp. : 69-75

Bentham Science Publishers

Access to resources Recommend Favorite